| Literature DB >> 35300721 |
Madeline G Roman1, Ryan Gutierrez1, Rachel Houston2.
Abstract
BACKGROUND: Marijuana (Cannabis sativa) is the most commonly used illicit drug in the USA, and the use of DNA barcodes could assist drug trafficking investigations by indicating the biogeographical origin and crop type of a sample and providing a means for linking cases. Additionally, the legality of marijuana in the USA remains complicated with some states fully legalizing marijuana for recreational use while federally marijuana remains completely illegal. Massively parallel sequencing (MPS) offers distinct advantages over capillary electrophoresis (CE), including more comprehensive coverage of target loci, analysis of hundreds of markers simultaneously, and high throughput capabilities.Entities:
Keywords: Cannabis sativa; Chloroplast DNA; Genetic assay; Massively parallel sequencing
Year: 2022 PMID: 35300721 PMCID: PMC8928601 DOI: 10.1186/s42238-022-00123-2
Source DB: PubMed Journal: J Cannabis Res ISSN: 2522-5782
Primer sequences and optimal annealing temperatures for single PCR reactions
| Region | Forward primer | Reverse primer | Product size (bp) | Ta (°C) |
|---|---|---|---|---|
| ACGAGCCAAAGTTTTAACACAGG | TCGGCTTTTAAGTGCGGCTA | 2111 | 69 | |
| AGAAAAGGGTGTAGACGAACG | TCGTTTCTCGGAGGCAAGAAT | 1398 | 66 | |
| TCTAATGATCCGGGGCGTAA | TGCATTCAAAACGACCTGC | 1668 | 66 | |
| ACGGCTCAGCAGTCAAGTTC | TTCGAAATTCATGAAAGGCCCC | 2095 | 68 | |
| GGCTGTTCAAACAGGTACAGG | TGCCGGAAATACTAAGCCCA | 1424 | 68 | |
| TAAATTCCCCTGTCGGTGCC | ATGCCTATTGGTGTTCCAAAAGTA | 1984 | 66 | |
| GGAAAAACCCACATACGGCG | TAACACTCGGCGCGGTTATT | 1964 | 69 |
Genotypes for polymorphisms in the trnK-matK-trnK region (2233–4337 bp)
| Sample name | trnK-matK-trnK INDEL (GAATAC) | trnK-matK-trnK SNP (C/T) | trnK-matK-trnK STR1 (A) | trnK-matK-trnK STR2 (T) | ||
|---|---|---|---|---|---|---|
| 2984 | 3258 | 3561 | 3752 | 3809 | 4109 | |
| Yoruba Nigeria (NC_027223.1) | Absent | C | T | A | 11 | 10 |
| H2-4 | Absent | C | T | A | 11 | 10 |
| H3-3 | Absent | C | T | A | 11 | 10 |
| H5-4 | Present | C | T | A | 11 | 10 |
| NT H5-1 | Absent | C | T | A | 11 | 10 |
| NT H5-2 | Present | C | T | A | 11 | 10 |
| NT H5-4 | Present | C | C | C | 15 | 9 |
| H8-1 | Present | C | T | A | 11 | 10 |
| 10-A1 | Present | C | T | A | 11 | 10 |
| 12-A7 | Present | C | T | A | 11 | 10 |
| 16-B1 | Present | C | C | C | 13 | 9 |
| 21-A16 | Present | C | T | A | 11 | 10 |
| 35 | Present | C | C | C | 15 | 9 |
| 41 | Present | C | C | C | 14 | 9 |
| MedMJ10 | Present | C | T | A | 11 | 10 |
Italics indicate polymorphisms not analyzed previously by CE
a Indicates new polymorphisms discovered in this study
Genotypes for polymorphisms in the rps16 region (4803–6201 bp)
| Sample name | rps16 SNP1 (A/G) | rps16 SNP2 (A/C) | rps16 hSTR (C) | rps16 SNP3 (G/A) | ||
|---|---|---|---|---|---|---|
| 4911 | 5197 | 5303 | 5517 | 5518 | 6103 | |
| Yoruba Nigeria (NC_027223.1) | Absent | 9 | A | A | 12 | G |
| H2-4 | Absent | 9 | A | A | 11 | G |
| H3-3 | Absent | 9 | A | A | 11 | G |
| H5-4 | Absent | 10 | A | A | 11 | A |
| NT H5-1 | Absent | 9 | A | A | 11 | G |
| NT H5-2 | Absent | 10 | A | A | 11 | A |
| NT H5-4 | Present | 11 | A | A | 13 | G |
| H8-1 | Absent | 10 | A | A | 11 | A |
| 10-A1 | Absent | 10 | A | A | 11 | A |
| 12-A7 | Absent | 10 | A | A | 11 | A |
| 16-B1 | Present | 11 | A | A | 14 | G |
| 21-A16 | Absent | 10 | A | A | 11 | A |
| 35 | Present | 11 | A | A | 13 | G |
| 41 | Present | 11 | A | A | 14 | G |
| MedMJ10 | Absent | 10 | A | A | 11 | A |
Italics indicate polymorphisms not analyzed previously by CE
a Indicates new polymorphisms discovered in this study
Genotypes for polymorphisms in the trnS-trnG region (8300–9967 bp). Discrepancies between the genotypes obtained by MPS and CE are indicated in parentheses
| Sample name | trnS-trnG SNP1 (T/C) | trnS-trnG SNP2 (A/T) | trnS-trnG hSTR1 (Variable) | trnS-trnG hSTR2 (T) | trnS-trnG SNP3 (T/A) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8359 | 8585 | 8595 | 8684 | 8685 | 8731 | 8877 | 9018 | 9104 | 9149 | 9360 | 9463 | |
| Yoruba Nigeria (NC_027223.1) | 7 | 10 | T | A | 9 | Absent | A | 15 | 11 | 12 | A | A |
| H2-4 | 7 | 10 | T | A | 9 | Absent | A | 15 | 11 | 12 | A | A |
| H3-3 | 7 | 10 | T | A | 9 | Absent | A | 15 | 11 | 12 | A | A |
| H5-4 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| NT H5-1 | 7 | 10 | T | A | 9 | Absent | A | 15 | 11 | 12 | T | A |
| NT H5-2 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| NT H5-4 | 8 | 12 | T | A | 8 | Absent | A | 16 | 12 (CE: 11) | 11 | T | C |
| H8-1 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| 10-A1 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| 12-A7 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| 16-B1 | 8 | 10 | T | A | 8 | Absent | T | 16 | 12 (CE: 11) | 11 | T | C |
| 21-A16 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
| 35 | 8 | 10 | T | A | 8 | Present | A | 16 | 12 (CE: 11) | 11 | T | C |
| 41 | 8 | 10 | T | A | 8 | Absent | T | 16 | 12 (CE: 11) | 11 | T | C |
| MedMJ10 | 8 | 10 | C | T | 9 | Absent | A | 15 | 11 | 12 | T | A |
Italics indicate polymorphisms not analyzed previously by CE
a Indicates new polymorphisms discovered in this study
Genotypes for polymorphisms in the ycf3 region (43,383–45,478 bp)
| Sample name | ycf3 hSTR1 (T) | ycf3 hSTR2 (T) | ycf hSTR3 (A) |
|---|---|---|---|
| 43454 | 44007 | 45034 | |
| Yoruba Nigeria (NC_027223.1) | 11 | 11 | 10 |
| H2-4 | 11 | 11 | 10 |
| H3-3 | 11 | 11 | 10 |
| H5-4 | 10 | 12 | 10 |
| NT H5-1 | 11 | 11 | 10 |
| NT H5-2 | 9 | 12 | 10 |
| NT H5-4 | 9 | 10 | 10 |
| H8-1 | 10 | 12 | 10 |
| 10-A1 | 10 | 12 | 10 |
| 12-A7 | 10 | 12 | 10 |
| 16-B1 | 9 | 10 | 10 |
| 21-A16 | 10 | 12 | 10 |
| 35 | 9 | 10 | 10 |
| 41 | 9 | 10 | 10 |
| MedMJ10 | 10 | 12 | 10 |
Genotypes for polymorphisms in the accD-psaI region (58,173–59,596 bp)
| Sample name | accD-psal SNP1 (A/G) | accD-psal SNP3 (A/C) | accD-psal SNP2 (T/G) | accD-psal STR (A) | ||
|---|---|---|---|---|---|---|
| 58833 | 58851 | 58921 | 58924 | 58981 | 59141 | |
| Yoruba Nigeria (NC_027223.1) | A | A | G | T | T | 10 |
| H2-4 | A | A | G | T | T | 10 |
| H3-3 | A | A | G | T | T | 10 |
| H5-4 | G | A | G | T | G | 11 |
| NT H5-1 | A | A | G | T | T | 10 |
| NT H5-2 | G | A | G | T | G | 11 |
| NT H5-4 | G | C | G | T | T | 10 |
| H8-1 | G | A | G | T | G | 11 |
| 10-A1 | G | A | G | T | G | 11 |
| 12-A7 | G | A | G | T | G | 11 |
| 16-B1 | G | C | A | C | T | 10 |
| 21-A16 | G | A | G | T | G | 11 |
| 35 | G | C | A | C | T | 10 |
| 41 | G | C | A | C | T | 10 |
| MedMJ10 | G | A | G | T | G | 11 |
Italics indicate polymorphisms not analyzed previously by CE
a Indicates new polymorphisms discovered in this study
Genotypes for polymorphisms in the clpP region (70,502–72,486 bp)
| Sample name | clpP hSTR1 (A) | clpP hSTR2 (Variable) | clpP hSTR3 (T) | clpP hSTR4 (T) | clpP INDEL (TTCAATTTA) |
|---|---|---|---|---|---|
| 70,912 | 70,981 | 71,663 | 72,016 | 72,028 | |
| Yoruba Nigeria (NC_027223.1) | 11 | TATTT | 14 | 13 | Absent |
| H2-4 | 11 | TATTT | 14 | 12 | Absent |
| H3-3 | 11 | TATTT | 14 | 12 | Absent |
| H5-4 | 10 | TTTT | 15 | 12 | Present |
| NT H5-1 | 11 | TTTT | 14 | 12 | Absent |
| NT H5-2 | 10 | TTTT | 15 | 11 | Present |
| NT H5-4 | 11 | TTTT | 12 | 11 | Absent |
| H8-1 | 10 | TTTT | 14 | 11 | Present |
| 10-A1 | 10 | TTTT | 15 | 11 | Present |
| 12-A7 | 10 | TTTT | 14 | 11 | Present |
| 16-B1 | 12 | TTTT | 11 | 10 | Absent |
| 21-A16 | 10 | TTTT | 15 | 11 | Present |
| 35 | 12 | TTTT | 11 | 10 | Absent |
| 41 | 12 | TTTT | 11 | 10 | Absent |
| MedMJ10 | 10 | TTTT | 15 | 11 | Present |
Genotypes for polymorphisms in the rpl32-trnL region (112,153–114,100 bp). Discrepancies between the genotypes obtained by MPS and CE are indicated in parentheses
| Sample name | rpl32-trnL hSTR1 (A) | rpl32-trnL hSTR2 (A) | rpl32-trnL SNP (A/C) | rpl32-trnL hSTR3 (Variable) | rpl32-trnL INDEL (TAAAAA) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 112,294 | 112,551 | 112,562 | 112,830 | 112,900 | 112,961 | 113,017 | 113,044 | 113,149 | 113,246 | 113,459 | |
| Yoruba Nigeria (NC_027223.1) | 8 | 12 | Absent | 12 | A | 11 | 10 | A | 8 (7T+A) | Present | A |
| H2-4 | 8 | 12 | Absent | 12 | A | 11 | 10 | A | 9( 8T+A) | Absent | A |
| H3-3 | 8 | 12 | Absent | 12 | A | 11 | 10 | A | 8 (7T+A) | Absent | A |
| H5-4 | 8 | 13 | GAATTG+10A | 11 | A | 11 | 10 | C | 6 (6A) | Present | A |
| NT H5-1 | 8 | 11 | Absent | 12 | A | 12 | 10 | A | 6 (2T+4A) | Present | A |
| NT H5-2 | 8 | 13 | GAATTG+11A | 11 | A | 11 | 10 | C | 6 (6A) | Present | A |
| NT H5-4 | 8 | 11 | GAATTG+10A | 11 | T | 11 (CE:12) | 11 | A | 11 (7T+4A) | Present | A |
| H8-1 | 8 | 13 | GAATTG+12A | 11 | A | 11 | 10 | C | 6 (6A) | Present | A |
| 10-A1 | 8 | 13 | GAATTG+11A | 11 | A | 11 | 10 | C | 6 (T+5A) | Present | A |
| 12-A7 | 8 | 13 | GAATTG+12A | 11 | A | 11 | 10 | C | 6 (6A) | Present | A |
| 16-B1 | 7 | 11 | GAATTG+10A | 11 | T | 11 (CE:12) | 11 | A | 14 (6T+8A) | Present | G |
| 21-A16 | 8 | 13 | GAATTG+11A | 10 | A | 11 | 10 | C | 6 (6A) | Present | A |
| 35 | 7 | 10 | GAATTG+10A | 11 | T | 11 (CE:12) | 11 | A | 15 (11T+4A) | Present | G |
| 41 | 7 | 10 | GAATTG+10A | 11 | T | 11 (CE:12) | 11 | A | 14 (6T+8A) | Present | G |
| MedMJ10 | 8 | 13 | GAATTG+11A | 11 | A | 11 | 10 | C | 6 (6A) | Present | A |
Italics indicate polymorphisms not analyzed previously by CE
a Indicates new polymorphisms discovered in this study